LeonaBio

LeonaBio P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of LeonaBio (LONA) as of Oct 22, 2026 is -2.03. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -0.95 — a change of 112.56% (lower).

P/FCF

-2.03

YoY

112.56%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of LeonaBio is 2025 -2.03 . P/FCF (Price-to-Free-Cash-Flow Ratio) of LeonaBio was 2024 -0.95 . It decreases by 112.56% lower compared to the previous year.

The LeonaBio P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-20.68 USD
Jan 1, 2019
-24.97 USD
Jan 1, 2020
-3.51 USD
Jan 1, 2021
-2.08 USD
Jan 1, 2022
-1.26 USD
Jan 1, 2023
-0.92 USD
Jan 1, 2024
-0.95 USD
Jan 1, 2025
-2.03 USD
The LeonaBio P/FCF history
YEARP/FCFYoY
-2.03+112.56%
-0.95+3.96%
-0.92-27.16%
-1.26-39.31%
-2.08-40.83%
-3.51-85.95%
-24.97+20.74%
-20.68—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LeonaBio Stock analysis

What does LeonaBio do? Athira Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, that generates revenue by developing small molecules to restore neuronal health and stop neurodegeneration. The firm utilizes its proprietary ATH platform to target and enhance the activity of a vital neuronal growth factor, creating a pipeline of drugs designed to cross the blood brain barrier for the central nervous system or target the peripheral nervous system. This technology underpins the development of ATH-1017, which is specifically intended for the treatment of neurodegenerative disorders with an initial focus on Alzheimer’s disease. The product aims to improve symptoms in cognitively impaired subjects by enhancing neuronal health and promoting regeneration, serving the medical needs of patients suffering from these conditions. LeonaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LeonaBio stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of LeonaBio is -2.03 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of LeonaBio changed from -0.95 to -2.03, representing a 112.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) LeonaBio since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s LeonaBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — LeonaBio

All Key Metrics — LeonaBio